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According to the updated International Myeloma Working Group criteria, smoldering multiple myeloma (SMM) is an asymptomatic plasma cell disorder characterized by an M-component >3 g/dL, 
bone marrow plasma cell infiltration >10% and <60%, and absence of 
any myeloma-defining event. Active multiple myeloma is preceded by 
SMM, with a median time to progression of approximately 5 years. 
Cases of SMM range from the extremes of “monoclonal gammopathy of 
undetermined significance-like”, in which patients never progress during 
their lifetimes, to “early multiple myeloma”, in which transformation 
into symptomatic disease, based on genomic evolution, may be rapid 
and devastating. Such a “split personality” makes the prognosis and man-
agement of individual patients challenging, particularly with regard to 
the identification and possible early treatment of high-risk SMM. 
Outside of clinical trials, the conventional approach to SMM generally 
remains close observation until progression to active multiple myeloma. 
However, two prospective, randomized trials have recently demonstrat-
ed a significant clinical benefit in terms of time to progression, and of 
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ABSTRACT
Introduction  
“Asymptomatic”, smoldering multiple myeloma 
(SMM) is in the middle of the continuum of monoclonal 
gammopathies. SMM is more advanced and carries a 
higher disease burden than monoclonal gammopathy of 
undetermined significance (MGUS), but does not show 
the clinical features of end-organ damage, nor any of the 
other myeloma-defining events of active multiple myelo-
ma (MM).1-5 
Of all patients with MM, 8-14%  have SMM: these 
patients have a median age of onset of 67 years, an annual 
incidence of 0.4 cases per 100,000 persons and a higher 
prevalence in Americans of African descent.6,7 The medi-
an time to progression to active MM is around 5 years, 
with a variable rate of approximately 10%/year during 
the first 5 years, 3%/year for the next 5 years, and 
1%/year thereafter.7,8 Thus, SMM is a heterogeneous enti-
ty, ranging from ‘MGUS-like’ to ‘early MM’, in which 
malignant plasma cells can rapidly expand and lead to 
active MM. Yet, nearly one third of cases of SMM will 
never progress. Such a “split personality” of SMM 
remains intriguing and challenging.9  
For decades, the conventional approach to SMM has 
been close observation, delaying treatment to the time of 
progression to active MM. Significant advances in the 
understanding of disease biology, improved risk stratifica-
tion, and newer therapies with better efficacy and lower 
toxicity contributed to deeper responses and longer sur-
vival for patients with active MM. These advances have 
also challenged the management of SMM, raising the 
question of whether earlier treatment could: (i) avoid or 
delay the progression to MM; (ii) prevent the severe com-
plications of end-organ damage; and (iii) potentially cure 
at least a proportion of patients with SMM. Thus, “to 
treat or not to treat” SMM, or even better, “are  there 
patients with SMM who would benefit more from early 




Here, a European Myeloma Network (EMN) Expert 
Panel updates 2016 European perspectives on SMM,4 
addressing current biological knowledge, new prognostic 
scoring systems and recent results of clinical trials, as well 
as providing practical recommendations. During two 
EMN Trialist meetings in 2019 and 2020, the areas of 
major concern in the management of SMM were selected 
by generating and rank-ordering key questions using the 
criterion of clinical relevance. Multistep procedures were 
utilized to achieve a consensus on recommendations. 
One panelist drafted the statements addressing the iden-
tified key questions. Subsequently, each panelist 
expressed his or her agreement with those statements 
and provided suggestions. The Delphi questionnaire 
method was used and a consensus of at least 80% was 




New insights into the molecular pathogenesis 
of smoldering multiple myeloma 
All cases of MM evolve through MGUS and SMM 
stages, although these are often not clinically evident.16 
The disease pathogenesis starts from intrinsic genomic 
defects in plasma cells, mainly translocations of onco-
genes under the control of regulatory elements of the 
immunoglobulin heavy chain (IGH) locus or multiple tri-
somies of odd-numbered chromosomes.17 However, 
these are not sufficient to cause the progression from 
MGUS to SMM or MM, as in most cases the clone will 
not evolve in a patient’s lifetime. Furthermore, high-risk 
translocations such as t(4;14) and t(14;16) are less fre-
quent in asymptomatic cases, while t(11;14) is more fre-
quent in SMM.18 These different frequencies reflect differ-
ent intrinsic propensities of the oncogenic translocation 
to drive symptomatic progression. Hyperdiploidy seems 
to slightly increase the risk of transformation to active 
MM as well.19 Interestingly, the number of chromosomal 
trisomies is lower in hyperdiploid MGUS than in hyper-
diploid SMM,20,21 suggesting that ongoing acquisition of 
genomic lesions may be the cause of progression. 
Consistently, secondary copy-number abnormalities, 
such as del(1p), amp(1q), del(16q), and del(17p)18,22 are also 
more frequent in MM than in SMM. Next-generation 
sequencing studies evidenced a globally lower number of 
mutations in MGUS and SMM than in MM.23,24 This was 
particularly true for mutations in KRAS, NRAS, FAM46C, 
but also for genes in the NF-κB pathway and DNA repair 
pathway genes.18 Conversely, high-risk SMM showed a 
landscape of mutations and chromosomal abnormalities 
more similar to that of MM.25 Indeed, single-cell studies 
have highlighted, within a clonal plasma cell population, 
the presence of subclones with distinct phenotypes that 
could be linked to malignant progression and prove the 
step-wise evolution of MM.26  
The analyses of paired SMM-MM genomes highlighted 
two patterns of progression: (i) evolution from minor or 
entirely new subclones, and (ii) no association with 
genomic changes.18,27-29 The former includes true asympto-
matic cases that need to acquire new lesions to shift their 
clinical behavior towards an aggressive phenotype. The 
latter are aggressive cases just about to meet clinical crite-
ria for progression, with generally a shorter time to evo-
lution.25 Indeed, accumulating evidence suggests that 
changes in clonal substructure can be used to monitor 
SMM before end-organ damage develops.18,30 Genomic 
events associated with SMM progression include translo-
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overall survival in one of the two studies, for some patients with higher-risk SMM treated with lenalido-
mide ± dexamethasone, raising the question of whether such an approach should be considered a new 
standard of care. In this paper, experts from the European Myeloma Network describe current biological 
and clinical knowledge on SMM, focusing on novel insights into its molecular pathogenesis, new prog-
nostic scoring systems proposed to identify SMM patients at higher risk of early transformation, and 
updated results of completed or ongoing clinical trials. Finally, some practical recommendations for the 
real-life management of these patients, based on Delphi consensus methodology, are provided.
cations between the IGH locus and the MYC onco-
gene25,30,31 and accumulation of complex rearrange-
ments.25,30,32 Last, the activity of mutational processes is 
different in MGUS/SMM and MM. Early mutations, 
acquired at the time of initiation, are caused by the DNA 
deaminase AID or from processes associated with cell 
aging. Late mutations, developing at the time of progres-
sion, arise from aberrant activity of the APOBEC family 
of cytidine deaminases, whose activity is absent in nor-
mal plasma cells.33-34 
In clinical practice, recurrent translocations or hyper-
diploidy can be assessed by fluorescence in situ hybridiza-
tion or multiplex ligation-dependent probe amplifica-
tion.35 Next-generation sequencing offers a more compre-
hensive evaluation of genomic lesions,36 but this approach 
must still be considered investigational and not a current 
standard.  
The progression of MM also depends on the tumor 
microenvironment.37,38 In particular, clonal plasma cells 
feed on proliferative and anti-apoptotic signals from stro-
mal cells, including interleukin-6, insulin-like growth fac-
tor 1 and vascular endothelial growth factor. Osteoblasts 
and osteoclasts play opposing roles, with reduced osteo-
protegerin secretion by osteoblasts and increased RANKL 
secretion by stromal cells promoting the activity of osteo-
clasts, which in turn secrete interleukin-6. In addition, 
progressive SMM is associated with increased neo-angio-
genesis, in which MM-induced endothelial cells carry 
specific gene expression signatures associated with dis-
ease evolution. Furthermore, immune cells in the 
microenvironment are actively involved in MM progres-
sion. Innate and acquired immunity may prevent clonal 
plasma cell growth in early asymptomatic stages,39 as 
indirectly shown by the unrestrained growth of plasma 
cells from asymptomatic patients xenografted into 
immunocompromised mice.40 In addition, single-cell 
studies have shown how clonal plasma cells may shape a 
permissive immune environment already from the 
MGUS stage. In a continuous pattern, progression from 
SMM to MM is also associated with reduced MHC class 
II expression in CD14+ monocytes, an increase of regula-
tory T cells, loss of memory cytotoxic cells with skewing 
towards effector cells with suppressed or anergic pheno-
type, and upregulated interferon signaling promoting 
immunosuppression and MM growth.41 While these find-
ings are less likely to be translated soon into clinical appli-
cations, the possibility of harnessing the immune 
microenvironment to generate diagnostic tests to predict 
progression, or even therapeutic approaches to halt pro-
gression, is intriguing. 
 
 
Current diagnosis and monitoring  
SMM is currently diagnosed according to International 
Myeloma Working Group (IMWG) criteria, based on 
amount of M-component, percentage of clonal bone mar-
row plasma cells (BMPC) infiltration and no evidence of 
end-organ damage (CRAB) or amyloidosis (Table 1).3 
Updated IMWG criteria re-classified 10-15% of patients 
previously diagnosed as having SMM,3 on the basis of 
new myeloma-defining events  (biomarkers of malignan-
cy:  >60% BMPC, free light chains [FLC] ratio >10042 and 
>1 focal lesion with magnetic resonance imaging [MRI]), 
the so-called “SLIM CRAB” criteria,  as “ultra-high-risk” 
SMM. These patients are considered eligible for full MM 
treatments, having a risk of progression of about 80% at 
2 years.  
The new IMWG criteria emphasize the role of imaging 
to risk-stratify SMM, with patients having two or more 
focal lesions >5 mm detected by MRI qualifying for active 
treatments.43,44 In particular, the IMWG recommends sen-
sitive low-dose whole-body CT for the staging of mono-
clonal gammopathies.45 This imaging technique was 
recently validated in a prospective study of 100 patients 
with SMM at different timepoints to identify early bone 
lesions related to MM evolution.46 If low-dose whole-
body CT is negative, whole-body or spine and pelvis 
MRI, where possible, should be pursued,43 although the 
latter MRI protocol can miss around 10% of non-axial 
lesions. Given the spatial distribution of focal bone 
lesions, it has been recently suggested that the cutoff for 
the number of focal lesions should be adapted according 
to the MRI protocol used.47 18F-fluorodeoxyglucose 
positron emission tomography (PET)-CT may be consid-
ered an appropriate alternative to low-dose whole-body 
CT. It is highly recommended to distinguish between 
SMM and active MM, if low-dose whole-body CT is neg-
ative and whole-body MRI is unavailable.48 In the case of 
uncertain or borderline lesions, radiological studies 
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Table 1. Current diagnostic criteria for monoclonal gammopathy of undetermined significance, smoldering multiple myeloma and multiple myelo-
ma, according to International Myeloma Working Group criteria. 
 Disease                           Criteria3 
 MGUS                                    Serum MC (non IgM type) <3 g/dL and clonal BMPC <10% 
                                                Absence of myeloma-defining events, such as end-organ damage (CRAB)*, or other biomarkers of malignancy (SLiM)**,  
                                                or amyloidosis, which can be attributed to the plasma cell proliferative disorder  
 SMM                                      Serum MC (IgG or IgA) >3 g/dL or urinary MC  >500 mg per 24 hours and clonal BMPC ≥10% and <60% 
                                                Absence of myeloma-defining events, such as end-organ damage (CRAB)*, or other biomarkers of malignancy (SLiM)*,  
                                                or amyloidosis, that can be attributed to the plasma cell proliferative disorder 
 MM                                         Clonal BMPC cells >10% or biopsy proven plasmacytoma and any one or more of myeloma-defining events, such as end-organ  
                                                damage (CRAB)*, or other biomarkers of malignancy (SLIM)*, or amyloidosis, which can be attributed to the plasma cell  
                                                proliferative disorder 
MGUS: monoclonal gammopathy of undetermined significance; MC: M-component; BMPC: bone marrow plasma cells;  SMM: smoldering multiple myeloma; MM: multiple myelo-
ma. * CRAB:  serum Calcium > 1 mg/dL above the upper limit of normal value or > 11 mg/dL;  Renal insufficiency: serum creatinine > 2 mg/dL or creatinine clearance < 40 
mL/min;  Anemia: hemoglobin  >2 g/dL below the lower limit of normal value or 10 g/dL; Bone lesions: one or more lytic lesions on skeletal radiography or computed tomography 
(including positron emission tomography). **SLiM: clonal bone marrow plasma cell percentage ≥ Sixty percent;  serum involved/uninvolved free LIght chains ratio >100;  
Magnetic resonance imaging: more than one focal lesion ≥5 mm.
should be repeated, preferably alternating different tech-
niques, every 3-6 months or whenever clinically indicat-
ed, until a definitive diagnosis of symptomatic MM is rea-
sonably made or excluded, (i.e., the suspicious lesion 
remains stable, is not accompanied by other signs of pro-
gression, or is disappearing). 
Clinical and laboratory monitoring of SMM should ini-
tially be performed every 2-3 months after diagnosis for 
6-12 months.49 If test results are stable, patients may be 
followed every 4-6 months for another year and every 6-
12 months thereafter. However, follow-up should be indi-
vidualized based on risk of progression. Despite the 
absence of prospective data, according to the Expert 
Panel, imaging evaluation might preferably be repeated 
annually with MRI (because of the higher sensitivity for 
early damage) for the first 5 years (then stopped or the 
frequency reduced) or at clinical suspicion/pain or pro-
gressive increase of M-component (low-dose whole-body 
CT or MRI). A detailed imaging algorithm for patients 
with SMM is reported in the recent IMWG consensus on 
imaging.43 
Importantly, combined, longitudinal evaluation and 
review of all relevant disease parameters may be required 
to interpret dynamics of the disease correctly.4 
 
 
New prognostic scores  
During the last years, several risk scores for SMM pro-
gression, combining routinely used laboratory parame-
ters, have emerged.4,8,9,49 These include the BMPC infiltra-
tion rate, an aberrant plasma cell phenotype (>95% clonal 
BMPC within the BMPC compartment), immunoparesis, 
the amount of serum M-component, an altered FLC ratio, 
and albumin levels.50-54  
Further studies have highlighted the prognostic value of 
additional factors: (i) a progressive increase of the M-
component and Bence-Jones proteinuria over time;55,56 (ii) 
an evolving decrease in hemoglobin;57 (iii) bone marrow 
biopsy characteristics;58 (iv) presence of circulating plasma 
cells and their proliferative activity in the bone mar-
row;59,60 (v) bone involvement detected by MRI or PET-CT 
imaging;61,62 (vi) cytogenetic and molecular features of the 
clonal population;22,63-65 and (vii) serum levels of B-cell mat-
uration antigen.66 In particular, a Southwest Oncology 
Group model, incorporating serum FLC values, serum M-
component and the University of Arkansas Medical 
Sciences 70-gene expression profile signature (GEP-70), 
predicted 2-year progression rates of 66.7%, 21.9% and 
3.4% in patients with two or three, one, and no risk fac-
tors, respectively, ranking  statistically first among other 
investigated clinical risk scores available at the time of 
analysis (Table 2).67   
Since ultra-high-risk SMM patients are now considered 
to have MM,3 previously defined risk stratification mod-
els need to be re-assessed. Researchers at Mayo Clinic re-
examined their initial cohort of 421 patients with SMM 
who met the 2014 IMWG criteria to re-classify risk fac-
tors for progression.68 The median time to progression to 
symptomatic MM was 57 months. Based on multivariate 
analysis data, a new Mayo risk model was proposed uti-
lizing the same three parameters previously identified in 
2008, but with different cut-offs: involved to uninvolved 
serum FLC ratio >20, serum M-component >2 g/dL, and 
BMPC infiltration >20% (20/2/20 SMM score, Table 2). 
On this basis, three risk groups were identified: low-risk: 
no risk factors; intermediate risk: one risk factor; high-
risk: two or more risk factors. The estimated median 
times to progression were 109.8 months, 67.8 months 
and 29.2 months, respectively. Criticisms of this model, 
however, could be that the cut-offs were developed due 
to best subgroup separations, the entire cohort and sub-
groups were limited, and a validation analysis was not 
available at the time of publication.   
A panel of IMWG experts recently conducted a larger, 
multicenter, retrospective study of 1,996 SMM patients 
diagnosed according to the 2014 IMWG criteria, to 
develop a robust risk stratification model69 (Table 2). The 
follow-up from diagnosis was 3 years. The median time 
to progression of the entire cohort was 6.4 years, while 
the 2-, 5-, and 10-year risks of progression were 22%, 
42% and 64%, respectively. Stepwise selection and mul-
tivariable analysis confirmed the value of 20/2/20 param-
eters and 1,363 patients with all three factors available 
were stratified in the same three categories, whose 2-
year progression rates were 6%, 18% and 44%, respec-
tively. Additional analyses were conducted in 689 
patients with a complete dataset by adding the presence 
of at least one of the following recurrent cytogenetic 
abnormalities: t(4;14), t(14;16), 1q gain, and del13q. 
Pooled data identified four risk categories, corresponding 
with 2-year risks of progression of 6%, 23%, 37%, and 
63% (Table 2). To define a scoring tool providing a more 
individualized risk assessment, the three original risk fac-
tors (involved to uninvolved serum FLC ratio, serum M-
component, and BMPC infiltration), together with cyto-
genetic abnormalities, were included in a new logistic 
regression model based on the entire range of values 
instead of using single cut points (Table 2). Using this 
approach, the 2-year risks of progression were 3.8% in 
patients with a total score of 0-4, 26% in those with a 
score 5-8, 51% in those with a score 9-12, and 73% 
when the score was >12.  
The Czech Myeloma Group recently developed a sim-
plified alternative model for SMM based exclusively on 
different serum parameters70 (Table 2). Data were collect-
ed from a training group of 287 patients and validated in 
an independent cohort of 240 patients. With a median fol-
low-up of 2.4/2.5 years in the two groups, progression to 
MM occurred in 52% and 39% of patients, respectively. 
The median risks of progression per year were 11% and 
10%, during the first 5 years after diagnosis, respectively. 
A serum FLC ratio of >30, immunoparesis (at least one 
uninvolved immunoglobulin below reference levels), and 
serum M-component ≥2.3 g/dL emerged as predictors of 
2-year progression rate in a combined multivariate analy-
sis. Based on these parameters, a new risk model was pro-
posed with four groups of patients defined by the pres-
ence of none, one, two or three of these risk factors. 
Notably, the 2-year risks of progression in the two 
cohorts were 79% and 80% for those patients with three 
risk factors.  
In a recently proposed “genomic model”, next-genera-
tion sequencing was applied in a retrospective cohort of 
214 patients with SMM, with whole exome sequencing 
performed on 166 tumors, and deep targeted sequencing 
on 48 tumors71 (Table 2). The model incorporated infor-
mation on DNA repair/MAPK pathway gene alterations 
and MYC aberrations. All these genomic abnormalities 
independently predicted progression after accounting for 
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clinical risk staging. Patients without such alterations had 
a median time to progression of 7.2 years versus 1.2 in 
those with one or more alterations. In addition, the risk 
was cumulative, and patients with two or more alter-
ations progressed the fastest. These results were validat-
ed in an external cohort of 72 patients with SMM previ-
ously sequenced. Importantly, this model outperformed 
the Mayo Clinic 2008 and 2018 prediction models.   
 
 
Early treatment  
Possible treatments of SMM vary considerably, with 
aims ranging from disease control, to delaying progres-
sion, and ideally cure (Table 3). Eight randomized, con-
trolled trials covering 885 patients were evaluated in a 
recent meta-analysis that compared early versus deferred 
treatment in SMM.72 These studies included patients 
treated with melphalan + prednisone,73-75 bisphospho-
nates ± thalidomide,76-78 siltuximab,79 and lenalidomide + 
dexamethasone.80,81 Overall, early treatment significantly 
decreased progression of SMM (risk ratio [RR] = 0.53, 
95% confidence interval [95% CI]: 0.33-0.87, P=0.01), 
particularly in patients receiving melphalan + prednisone 
(RR=0.22, 95% CI: 0.08-0.64, P=0.005) or immunomodu-
latory drugs (RR=0.43, 95% CI: 0.31-0.59, P<0.00001), 
and in the high-risk SMM subgroup (RR=0.51, 95% CI: 
0.37-0.70, P=0.0001). In the latter patients, treatment of 
SMM also significantly decreased mortality (RR=0.53, 
95% CI: 0.29-0.96, P=0.04). Regarding the most relevant 
adverse events, the risk of secondary primary malignan-
cies was significantly increased with early treatment 
(RR=4.13, 95% CI: 1.07-15.97, P=0.04). Major criticisms 
to this meta-analysis were the wide heterogeneity of 
therapeutic approaches used and the lack of risk stratifi-
cation in all but one trial.  
Treatment options with novel agents 
Lenalidomide 
The results of two phase III, prospective studies have 
been fully published, providing support to the use of 
lenalidomide (± dexamethasone) in patients with high-
risk SMM.  
The Spanish QuiRedex phase III trial (NCT00480363) 
was a pivotal study conducted in 119 patients with high-
risk SMM, defined by the presence of both BMPC >10% 
and M-component >3 g/dL or, if only one criterion was 
present, patients had to have <95% aberrant BMPC by 
immunophenotyping plus immunoparesis. Patients were 
randomized to receive nine 4-week induction cycles 
with lenalidomide + dexamethasone followed by main-
tenance with lenalidomide alone for 2 years or to under-
go observation.80,81 The primary endpoint was time to 
progression. Updated results after a median follow-up of 
10.8 years revealed a 46% reduction in the risk of death 
(hazard ratio [HR]=0.54; 95% CI: 0.3-0.9; P=0.034) and 
73% in that of progression (HR=0.27; 95% CI: 0.16-0.42; 
P<0.0001) for early treatment versus observation.82 The 
median overall survival had not been reached in the 
treatment arm, while it was 7.8 years in the control arm. 
The updated median time to progression was 9.0 versus 
2.1 years in patients receiving treatment and in the con-
trol group, respectively. No differences were observed 
between arms when overall survival was compared from 
the start of subsequent therapy in patients who pro-
gressed to active MM, suggesting that, once the patient 
has progressed, lenalidomide treatment would not 
induce the appearance of resistant clones. The frequency 
of secondary primary malignancies was higher in the 
treatment group than in the observation group (10% vs. 
2%), but the cumulative risk did not differ significantly 
(P=0.07). Extensive phenotypic studies suggested that 
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Table 2. Most recent prognostic models for smoldering multiple myeloma. 
 Model                  Risk factors                                                                   Risk Group                                                              2-year           Median TTP  
                                                                                                                                                                                              PD rate (%)          (months) 
 SWOG 201467            MC >3 g/dL, sFLC >25 mg/dL, GEP-70 >0.26                        Low (0 factors), n=60                                                           3.4 
                                                                                                                                             Intermediate (1 factor), n=39                                           21.9 
                                                                                                                                             High (≥2 factors), n=18                                                      66.7 
 Mayo 201868              sFLCr >20, MC >2 g/dL, BMPC >20%                                     Low (0 factors), n=143                                                         9.7                        109.8 
                                                                                                                                             Intermediate (1 factor), n=121                                         26.3                        67.8  
                                                                                                                                             High (≥2 factors), n=153                                                    47.4                        29.2  
 IMWG 202069            MC >2 g/dL, sFLCr >20,  BMPC >20%                                   Low (0 factors), n=522                                                          6 
                                                                                                                                             Intermediate (1 factor), n=445                                          18 
                                                                                                                                             High (≥2 factors, n=396                                                        44 
                                    + high risk cytogenetics: [t(4;14), t(14;16),                         Low (0 factors/score 0-4) *, n=241                                 6/3.8   
                                    +1q, del(13q)]                                                                             Low-intermediate (1 factor/score 5-8), n=264           22/26.2 
                                                                                                                                            Intermediate (2 factors/score 9-12), n=233              45.5/51.1 
                                                                                                                                             High (3-4 factors/score >12), n=51                             63.1/72.5 
 CMG 202070               Immunoparesis (at least one uninvolved                             Low (0 factors), n=48/26 **                                         8.5 / 5.3 ** 
                                    immunoglobulin below reference levels),                           Intermediate (1 factor), n=44/34                                 20.9 / 7.5 
                                    sFLCr >30, MC ≥2.3 g/dL                                                           High (2 factors), n=32/41                                               41.9 / 44.8 
                                                                                                                                             Very high (3 factors), n=15/12                                      78.7 / 81.3 
 Dana Farber           DNA repair pathway gene alterations [mutations              0 factors, n=58                                                                       86.4 
 202071                         in TP53 and ATM, del(17p)], MAPK pathway gene              At least 1 factor, n=24                                                          14.4  
                                    mutations (KRAS, NRAS), MYC aberrations  
                                    (translocations or copy-number variations).                                                                                                                              
PD: progressive disease; TTP: time to progression; SWOG; Southwest Oncology Group;.MC: monoclonal component; sFLC: serum free light chains; sFLCr: serum free light chain 
ratio; BMPC: bone marrow plasma cells; GEP-70: University of Arkansas Medical Sciences 70-gene expression profile signature;  CMG: Czech Myeloma Group. *sFCLr score: <10: 
0; 10-25: 2; >25-40: 3; >40: 5. MC score: 0-1.5 g/dL: 0; >1.5-3 g/dL: 3; >3 g/dL: 4. BMPC score: 0-15%: 0; >15-20%: 2; >20-30%: 3; >30-40%: 5;  >40%: 6.  ** Validation cohort.
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Table 3. Update of clinical trials in smoldering multiple myeloma with currently available results. Other ongoing studies without published results are 
reported in the text of the paper. 
                          Phase, n, of       Treatments                                Risk stratification                   Primary endpoint,             ORR, CR, MRD            PFS, TTP, OS 
                          patients                                                                                                             FU 
 QuiRedex            III, n=119             Induction: 28-day cycle                  High-risk by BMPC >10%          TTP                                          After induction:             Median TTP: 
 NCT00480363                                      [C1-9]                                                and MC >3 g/dL or,                                                                        ORR 79%, CR: 14%         9.0 vs. 2.1 years   
 [80-82]                                                Lenalidomide 25 mg                       if only one criterion                   Median FU: 10.8 years                                                    (P=0.034) 
                                                               p.o. days 1–21 + Dex 20 mg          present, BMPC                                                                               After maintenance:  
                                                               p.o. days 1–4, 12–15;                       with aberrant phenotype                                                             ORR 90%, CR 26%          Median OS: 
                                                               Maintenance: 28-day cycle            >95% plus immunoparesis                                                                                                    NR vs. 7.8 years  
                                                               [C1-24] Lenalidomide                                                                                                                                                                         (P<0.0001) 
                                                               10 mg p.o days 1–21 (n=57)          
                                                               Observation (n=62)                                                                                                                                  ORR/CR: 0% 
 SWOG E3A06       III, n=182             Continuous therapy:                      Intermediate or high-risk          PFS                                           ORR 50%, CR 0%            3-year PFS: 
 NCT01169337                                      28 day-cycle [C1 – PD]:                 by BMPC >10%, or sheets                                                                                                      91%  vs. 66%  
 [84]                                                      Lenalidomide 25 mg                       and FLC  ratio <0.26                   Median FU:                                                                       (P=0.002) 
                                                               p.o. days 1–21                                   or >1.65                                         35 months 
                                                               (n=90)  
                                                               Observation (n=92)                                                                                                                                  ORR 0% 
 NCT01572480       II, n=18                Induction: 28-day cycle                  High-risk by PETHEMA               ORR, MRD                              ORR 100%,                      Estimated  
 [23,85]                                                 [C1-8]: Carfilzomib                         and  MAYO 2008 criteria                                                              MRD negativity:              4-year PFS: 71%  
                                                               20/36 mg/m2 i.v.                                                                                          Median FU:                            92% by MFC,                    
                                                               days 1,2, 8, 9, 15, 16 +                                                                              43.3 months                           75% by NGS,                    Estimated 
                                                               Lenalidomide 25 mg                                                                                                                                                                             4-year OS: 100% 
                                                               p.o. days 1–21 + Dex                      
                                                               20 mg (C1 – 4) and 10  
                                                               (C5– 8) p.o. or i.v.  
                                                               days 1, 2, 8, 9, 15, 16  
                                                               Maintenance: 28-day cycle  
                                                               [C1 – 24] Lenalidomide  
                                                               25 mg days 1–21    
GEM-CESAR        III, n=90               Induction: 28-day-cycle                  High-risk by PETHEMA               MRD                                         ORR: 98%                        PFS 93% 
 NCT02415413                                      [C1-6]: Carfilzomib                        criteria (ultra-high risk                                                               post-induction,               (5 biochemical 
 [87,88]                                                 20/36 mg/m2 i.v.                                 patients were included,             Median FU:                            98% post-AuSCT, 100% progressions) 
                                                               days 1,2, 8, 9, 15, 16                          ref. 3)                                            32 months                               post-consolidation  
                                                               + Lenalidomide 25 mg                                                                                                                             and maintenance;  
                                                               p.o. days 1–21 + Dex  
                                                               40 mg days 1, 8, 15, 22                                                                                                                               ≥CR: 38.4%, 61.5%  
                                                               AuSCT: Melphalan 200 mg/m2                                                                                                                   and 68.6% at the same  
                                                               Consolidation: KRd                                                                                                                                    time-points 
                                                               as induction for 2 cycles                                                                                                                          MRD negativity  23%,  
                                                               Maintenance: 28 day-cycle                                                                                                                       44% and 55% at the 
                                                               Lenalidomide 10 mg                                                                                                                                  same time points  
                                                               days 1–21 + Dex 20 mg  
                                                               days 1, 8,15, 22 for 2 years  
 NCT02697383       Pilot study,          Induction: 28-day cycle                  High-risk by  PETHEMA             ORR                                         ORR 64% (no CR)          No progression 
 [89]                       n=14                     [C1-12] Ixazomib 4 mg p.o.           or Mayo 2008 criteria                                                                                                               to MM 
                                                               days 1, 8, 15 + Dex 40 mg                                                                       Median FU 17 months  
                                                               p.o. days 1, 8, 15, 22 
                                                               Maintenance: 28-day cycle  
                                                               [C1-24] Ixazomib 4 mg p.o.  
                                                               days 1, 8, 15 
 NCT02916771       II, n=26                Induction: 28-day-cycle                  High risk, (ref. 8)                        PFS                                           ORR 89%, CR 19.2%      No progression 
[90]                        (56 planned)       [C1-9]: Ixazomib 4 mg                                                                                                                                                                         to MM 
                                                               p.o. days 1, 8, 15 +                                                                                    Median number  
                                                               Lenalidomide 25 mg p.o.                                                                        of cycles: 8 
                                                               days 1–21 + Dex 40 mg  
                                                               p.o. days 1, 8, 15, 22 
                                                               Maintenance: 28-day cycle  
                                                               [C10-24]: Ixazomib 4 mg p.o.  
                                                               days 1, 8, 15 + Lenalidomide  
                                                               15 mg p.o. days 1–21 (n= 45) 
 CENTAURUS       II, n=123              Daratumumab 16 mg/kg i.v.           Intermediate or high-risk         CR and PD/DR ratio              ORR 56%, CR 4.9%,        2-year PFS: 89.9%  
 NCT02316106                                      in 8-week cycles:                             by BMPC  ≥10% and <60%                                                                                                      extended intense,   
 [92]                                                      Extended intense (n=41):           and at least one of                      Median FU 26 months         PD/DR 0.059                     vs.82.0%  
                                                               [C1] every 1 week; [C2-3]            the following: MC                                                                                                                     intermediate  
Continued on the following page
EMN consensus on smoldering multiple myeloma
haematologica | 2021; 106(11) 2805
                                                               every other week; [C4-7]             ≥3 g/dL (IgA ≥2 g/dl),                                                                                                              intense vs. 75.3% 
                                                               every  4 weeks;                                urine MC >500 mg/24 h,                                                                                                          short dosing  
                                                               [C8-20] every 8 weeks                   FLC ratio <0.126 or >8 
                                                               Intermediate intense (n=41):                                                                                                               ORR 54%, CR 9.8%,  
                                                               [C1] every 1 week and                                                                                                                             PD/DR 0.107 
                                                               [C2-20] every 8 weeks 
                                                               Short dosing (n=41): [C1] every                                                                                                           ORR,38%, CR 0%,  
                                                               1 week                                                                                                                                                           PD/DR 0.150 
 NCT02960555       II, n=24                Isatuximab 20 mg/kg i.v.                 High-risk (criteria NA)               ORR                                         ORR 64%, CR  5%,         NA 
 [96]                       (planned             in 4 week cycle [C1] every                                                                                                                      with MRD negativity  
                                n. 61)                    1 week;  [C2-6] every other                                                                   Median number  
                                                               week; [C7-30] every 4 weeks                                                                of cycles: 11.5 
 NT01441973         II, n=31                Elotuzumab 20 mg/kg i.v.               High risk by MC ≥3 g/dL             Relationship CD 56dim           ORR 10%                         2-year PFS 69%  
 [97]                                                      [C1] days 1, 8, then                         with BMPC ≥10%; or MC            NK cells and MC                   (cumulative)                   (cumulative)  
                                                               [C2-progressive disease]             1–3 g/dL (alternatively             protein reduction 
                                                               monthly every  4 weeks                 urine MC >200 mg/24 h),          (not found)  
                                                                                                                            BMPC ≥10% and FLC ratio  
                                                               Elotuzumab 10 mg/kg i.v.               <0.125 or >8.0                              FU at least 28 months 
                                                               [C1] days 1, 8, 15, 22, then             
                                                               [C2- progressive disease]  
                                                               monthly every 2 weeks  
 NCT02279394       II, n=50                Induction: 28-day cycle                  High-risk, (ref. 8)                        PFS                                           ORR 84%, CR 6%            No progression 
 [98]                                                      [C1-2] Elotuzumab 10 mg/kg                                                                                                                                                               to MM 
                                                               i.v. days 1, 8, 15, 22 +                                                                               FU NA 
                                                               Lenalidomide 25 mg p.o. days      
                                                               1–21 + Dex 40 mg p.o.  
                                                               days 1, 8, 15, 22 
                                                               [C3-8]: Stem cell collection;  
                                                               Elotuzumab 10 mg/kg i.v.  
                                                               days 1, 15 + Lenalidomide  
                                                               as 25 mg p.o. days 1–21 +  
                                                               Dex 40 mg p.o. days 1, 8, 15 
                                                               Maintenance: 28-day cycle  
                                                               [C9-24] Elotuzumab 10 mg/kg  
                                                               i.v. days 1 + Lenalidomide 25 mg  
                                                               p.o. days 1–21 
 NCT02603887       Pilot study,          Pembrolizumab 200 mg i.v.           Intermediate to high risk          ORR                                         ORR 8%, CR 8%,             15% of patients  
 [99]                       n=13                     every 3 weeks × 8 cycles;             by either PETHEMA, Mayo                                                          MRD negativity 8%         progressed  
                                                               with  option  to continue up         2008 or SWOG criteria               Median number                                                               to MM 
                                                               to 24 cycles if continued                                                                        of cycles: 8  
                                                               benefit                                                
 NCT01484275       III, n=85               Siltuximab 15 mg/kg i.v. in              High risk by BMPC >10%          PFS                                           NA                                      1-year PFS: 84.5%  
 [79]                                                      2 h every 4 weeks (n=43)             and either MC >3 g/dL, or                                                                                                      siltuximab 
                                                               [C1-progressive disease]            FLC ratio <0.126 / >8                 Median FU                                                                        vs. 74.4%  
                                                               (n=43)                                               and  MC >1 / <3 g/dL                  29.2 months                                                                      observation 
                                                                                                                            (32%  ultra-high risk; ref 3)                                                                                                   (P<0.06) 
 
                                                                                                                                                                                                                                                                                  Median PFS: NR 
                                                               Observation (n=2)                                                                                                                                                                               siltuximab vs.: 
                                                                                                                                                                                                                                                                                  23.5 months 
                                                                                                                                                                                                                                                                                  observation 
                                                                                                                                                                                                                                                                                  OS not reached 
                                                                                                                                                                                                                                                                                  in both arms  
 NCT01718899       I-IIa, n=20           PVX-410 vaccine cohort                  Moderate to high risk by           Safety and immune              Immune response        PVX-410-alone: 
 [100]                                                    (n=3+6) 0.4-0.8 mg s.c.;                MC ≥3 g/dL, BMPC >10%,         response                                95%; (10/11 PVX-410      3 progressions 
                                                               every 2 weeks × 6 doses               abnormal FLC ratio                                                                      monotherapy,                 to MM (median 
                                                               PVX-410 combination cohort        (0.26-1.65)                                                                                       9/9 PVX-410                     TTP 36 weeks)  
                                                               (n=10): PVX-410 vaccine               Moderate (2 risk factors)                                                           combination) 
                                                               0.8 mg s.c. every 2                           or high risk (3 risk factors)                                                                                                   Combination  
                                                               weeks × 6 doses +                                                                                                                                                                              cohort:  
                                                               Lenalidomide  25 mg p.o.                                                                                                                                                                    1 progression 
                                                               days 1-21 every 28 days                                                                                                                                                                        to MM,  median  
                                                               × 3 cycles                                                                                                                                                                                                TTP NR 
FU: follow-up, ORR: overall response rate; CR: complete remission; MRD: minimal residual disease, PFS: progression-free survival; TTP: time to progression; OS: overall survival; C: cycle; p.o.: 
per os; i.v. intravenous; s.c.: subcutaneous; BMPC: bone marrow plasma cells; MC: M-component; KRd: carfilzomib, lenalidomide, dexamethasone; NR: not reached; FLC: free light chains; 
Dex: dexamethasone; MFC:  multicolor flow cytometry; NGS: next generation sequencing; AuSCT: autologous stem cell transplantation; NA, not available; NK: natural killer; MM: multiple 
myeloma; PD/DR:  progressive disease/death rate per patient-year ratio; Mayo 2008: ref. 51; PETHEMA: ref. 50; SWOG: ref. 66. 
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the impaired immune system of high-risk SMM patients 
could be reactivated by the immunomodulatory activity 
of lenalidomide.83  
The Eastern Cooperative Oncology Group E3A06 phase 
III trial (NCT01169337) assessed the efficacy of lenalido-
mide monotherapy compared with observation in 
patients with intermediate- or high-risk SMM.80 
Lenalidomide was administered orally as a single agent 
until disease progression, toxicity, or withdrawal for other 
reasons. Response to therapy was observed in 50% of 
patients in the lenalidomide arm, with no responses in the 
observation arm. With a median follow-up of 35 months, 
progression-free survival (the primary endpoint of the 
study) was significantly longer with lenalidomide than 
with observation (HR=0.28; 95% CI: 0.12-0.62; P=0.002), 
indicating a 72% decrease in the risk of progression. The 
most pronounced and significant benefit was seen in 
patients with high-risk SMM, as defined by both 2008 and 
2018 Mayo Clinic risk models. Six deaths occurred, two in 
the lenalidomide arm and four in the observation arm. 
Grade 3 or 4 non-hematologic adverse events were 
observed in 25 patients (28%) on lenalidomide and in 
none of the control group. The treatment discontinuation 
rate was 50%, (in 40% of cases due to adverse events). 
Secondary primary malignancies occurred in 5.2% and 
3.5% of treated and untreated patients, respectively. At 
the time of publication, data were not mature for evalua-
tion of overall survival.  
Several different, more intensive treatments are being or 
are close to being tested in SMM. Such approaches, briefly 
described below, generally comprise triplets including a 
proteasome inhibitor with an immunomodulatory drug + 
dexamethasone, monoclonal antibodies or even autolo-
gous stem cell transplantation. These new strategies, how-
ever, have so far generally been explored only in pilot stud-
ies with a limited number of patients or in phase II trials, 
with still preliminary results.  
Carfilzomib, lenalidomide and dexamethasone 
In a US pilot study (NCT01572480) in high-risk SMM, 
the carfilzomib, lenalidomide + dexamethasone (KRd) 
regimen resulted in an overall response rate of 100%.23,85 
Very high rates of minimal-residual disease (MRD) nega-
tivity, as determined by multiparametric flow cytometry 
(92%) or next-generation sequencing (75%), were 
observed. After a median potential follow-up of 43.3 
months, 63% of patients remained MRD-negative, with 
estimated 4-year progression-free and overall survival 
rates of 71% and 100%, respectively. The safety profile 
was consistent with previous reports for this regimen.  
A subsequent phase II study in high-risk SMM (Mayo 
Clinic or PETHEMA models) assessed KRd (8 cycles) + 
lenalidomide maintenance (KRd-R).86 After a median 
potential follow-up of 27.3 months, the overall response 
rate was 100% and 78% of patients achieved a best 
response of stringent complete remission. The primary 
objective of MRD-negative complete remission was 
achieved by 70.2%, with a median duration of 5.5 years. 
At the 5-year landmark, only 10% of patients had devel-
oped MM. No patient died, while grade 3-4 treatment-
related adverse events occurred in 33% of patients, the 
most frequent being cytopenias, thromboembolism, rash, 
and lung infection.  
Another ongoing multicenter, open-label phase II trial 
by the HOVON group is randomizing patients with high-
risk SMM, defined according to both the Mayo Clinic52 
and Spanish51 criteria, and with ultra-high-risk SMM, as 
defined by the IMWG,3 to treatment with a KRd combi-
nation versus lenalidomide + dexamethasone alone for 
nine cycles, followed by lenalidomide maintenance for 2 
years (NCT03673826). 
Among studies examining potentially curative strate-
gies, the GEM-CESAR trial is a phase II, single-arm trial 
focusing on SMM patients at high risk of progression to 
active MM (>50% at 2 years), according to Spanish crite-
ria (NCT02415413), and patients with ultra-high-risk 
SMM.87,88 The induction therapy in this trial is six 4-week 
cycles of KRd, high-dose melphalan and autologous stem 
cell transplantation as intensification therapy, followed 
by two KRd consolidation cycles and maintenance with 
lenalidomide + dexamethasone for up to 2 years. The pri-
mary endpoint is a sustained MRD-negativity rate of at 
least 50%, as determined by next-generation flow cytom-
etry after induction and transplantation. At a first analysis 
of 90 patients younger than 70 years,87 main grade 3-4 
toxicities during induction and maintenance treatments 
included neutropenia (6%), thrombocytopenia (11%), 
infections (18%) and skin rash (9%). With a median fol-
low-up of 32 months, 98% of patients remained alive and 
93% progression-free, with only five patients having had 
biochemical relapses. Updated results88 indicate that the 
overall response rate was 98% after induction, 98% after 
autologous stem cell transplantation, and 100% after con-
solidation; 68.6% of patients reached complete remission 
or better after consolidation, with 55% of them achieving 
MRD negativity.  
Ixazomib-based regimens 
A combination of ixazomib + dexamethasone has been 
evaluated in a small pilot study in high-risk SMM89 
(NCT02697383). At the time of the first analysis, with a 
median follow-up of 17 months, ten patients were con-
tinuing treatment: nine of them had achieved at least very 
good partial remission and no patient had progressed to 
symptomatic MM. Grade 3 non-hematologic adverse 
events included one intestinal complication and two 
grade 3 lung infections.  
The oral triplet ixazomib, lenalidomide + dexametha-
sone for nine cycles followed by 15 cycles of ixazomib + 
lenalidomide was investigated in patients with high-risk 
SMM in a phase II trial.90 Based on preliminary results in 
the first 26 patients, grade 3 hypophosphatemia, leukope-
nia, and neutropenia occurred in about 10% of patients, 
while 8% developed grade 4 neutropenia and hyper-
glycemia. The overall response rate in patients who 
received at least three cycles of treatment was 89% 
(23/26), including five complete responses (19.2%). None 
of the patients had shown progression to overt MM at the 
time of the analysis.  
 
 
Monoclonal antibodies  
As for other hematological malignancies, monoclonal 
antibodies are currently also being tested in SMM.91  
Daratumumab (anti-CD38) 
The randomized phase II CENTAURUS study 
(NCT02316106) evaluated daratumumab as a single agent 
in three different treatment schedules (extended intense, 
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extended intermediate, or short dosing) in 123 patients 
with intermediate/high-risk SMM.92 The main endpoints 
were a complete remission rate >15% and the progres-
sive disease/death rate per patient-year ratio. After a 
median follow-up of 26 months, the complete remission 
rates were 4.9%, 9.8%, and 0% for patients treated with 
the intense, intermediate, and short dosing schedules, 
respectively. Favorable progressive disease/death rate 
ratios and a median progression-free survival longer than 
2 years were observed in all arms. Two-year progression-
free survival rates for intense, intermediate, and short 
dosing were 89.9%, 82%, and 75.3%, respectively. 
Target-saturating trough concentrations were generally 
preserved by intense dosing. No new safety issues 
occurred.  
Based on these data, the long dosing schedule is being 
investigated in the ongoing, randomized phase III 
AQUILA study (NCT03301220) comparing subcutaneous 
daratumumab for up to 39 cycles versus active observa-
tion.93 The study will randomize about 360 patients with 
high-risk SMM according to one or more of the following 
features: serum M-component ≥3 g/dL, IgA SMM, 
immunoparesis, serum FLC ratio of ≥8 but <100, BMPC 
percentage in the range of 51% to 60%.  
Another phase III, randomized trial is comparing 
lenalidomide + dexamethasone versus daratumumab, 
lenalidomide + dexamethasone in high-risk SMM 
(NCT03937635, DETER-SMM) patients, with overall sur-
vival as the primary endpoint. A target of 288 patients 
diagnosed within 1 year and having an abnormal serum 
FLC ratio (≤0.125 or ≥ 8.0) and involved chain <100 
mg/L), and/or serum M-component >3 g/dL and/or pres-
ence of t(4;14) or del 17p or 1q will be enrolled.  
The ongoing, phase II ASCENT trial (NCT03289299) is 
evaluating daratumumab, carfilzomib, lenalidomide and 
dexamethasone (DKRd) without autologous stem cell 
transplantation in high-risk SMM.94 Treatment consists of 
12 DKRd cycles, followed by maintenance with lenalido-
mide and daratumumab for 12 cycles. Preliminary safety 
data on 46 patients who reported grade 3-4 adverse 
events documented cytopenia, thromboembolic events, 
infections, hypertension, diarrhea, and allergic reactions, 
which all occurred in less than 10% of subjects. The rela-
tive median dose intensity was ≥80% for all drugs, 
demonstrating the feasibility of such an approach. 
Single-agent daratumumab given intravenously for up 
to 20 cycles is also being evaluated in a phase II study in 
lower-risk SMM (NCT03236428).95 Feasibility was 
demonstrated in 28 patients. Response rates were 
assessed in 15 patients who completed six or more cycles: 
Partial response and at least very good partial response 
were achieved in 53% and 20% of these patients, respec-
tively. Thus far, no deaths, progression or therapy discon-
tinuations due to toxicity have occurred.  
Isatuximab (anti-CD38) 
A phase II study (NCT02960555) is exploring the effica-
cy of isatuximab (20 mg/kg intravenously) in high-risk 
SMM; the drug is administered at decreasing intervals up 
to 30 weeks.96 The median number of cycles given in the 
first 24 evaluable patients was 11.5 (range, 6-30). Five 
patients interrupted treatment, two because of progres-
sion to active MM. No deaths occurred during the study. 
Five grade 3 treatment-related adverse events [dyspnea, 
infusion related reactions, headache, neutropenia, urinary 
tract infections] were observed, all of which resolved to 
baseline. Best responses included partial remission (42%), 
very good partial remission (17%), and complete remis-
sion with MRD negativity by multiparameter flow 
cytometry at 10-5 (5%). This study also evaluated health-
related quality of life scores, suggesting that isatuximab 
may reduce anxiety and worry of progression to MM, 
with improvement of the score after six cycles.  
A phase III, randomized, multicenter study comparing 
isatuximab, lenalidomide + dexamethasone versus 
lenalidomide + dexamethasone in higher-risk SMM 
(according to IMWG criteria) within 5 years is about to 
start (NCT04270409). An initial safety run-in phase will 
confirm the recommended dose of isatuximab. Primary 
endpoints will include safety and efficacy (progression-
free survival), while pharmacokinetic and immunological 
studies, percentages, duration and quality of responses 
(including MRD), type of progression, second progres-
sion-free survival, overall survival, economic and health-
related quality of life evaluations will be  secondary 
objectives. 
Elotuzumab (anti-SLAMF7/CS1) 
Elotuzumab monotherapy had modest activity in SMM 
patients (overall response rate, 10%,) in a phase II trial 
(NCT01441973).97 However, duration of response and the 
2-year progression-free survival of 69% in some patients 
with high-risk characteristics were of some interest. In 
that study, no relationship emerged between baseline 
CD56dim NK cells and response. 
Another phase II trial (NCT02279394), tested elo-
tuzumab, lenalidomide + dexamethasone in high-risk 
SMM.98 This combination induced partial remissions or 
better, including three complete remissions and 18 very 
good partial remissions, in 41 of 50 patients (84%). 
Genomic studies revealed that mutations occurring in 
genes involved in DNA repair were associated with poor 
response. No progression to symptomatic MM was 
observed and the toxicity profile was manageable, 
although some thromboembolic events occurred. 
Pembrolizumab (anti-PD1) 
The checkpoint inhibitor pembrolizumab was investi-
gated in 13 patients with intermediate/high-risk SMM 
(NCT02603887).99 After a median of eight cycles, 11 
patients (85%) had stable disease, one patient progressed 
and one patient with 17p deletion and a high-risk gene-
expression signature reached MRD negativity at 10-4 by 
next-generation sequencing in bone marrow which per-
sisted after 27 months. Three patients discontinued the 
treatment due to immune-related adverse events.  
Siltuximab (anti-interleukin-6) 
A randomized, double-blind, placebo-controlled study 
evaluated interleukin-6 blocking with siltuximab in 85 
patients with high-risk SMM (NCT01484275).79 After a 
median follow-up of 29.2 months, the 1-year progres-
sion-free survival rate was 84.5% with siltuximab and 
74.4% with placebo. The median progression-free sur-
vival was not reached with siltuximab whereas it was 
23.5 months with placebo (P=0.057). Adverse events in 
the experimental arm were mainly of grade 2-3, the most 
common and serious ones being infections and urinary 
complications. Three deaths occurred with siltuximab 
and four with placebo. 
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Vaccines 
PVX-410 is a vaccine composed of a combination of 
four peptides, specifically targeting the highly overex-
pressed plasma cell antigens XBP1, CD138 and 
CS1/SLAMF7. A phase I/IIa multicenter, dose-escalation 
study (NCT01718899) accrued 22 patients with SMM at 
moderate or high risk of progression who received PVX-
410, with or without lenalidomide.100 The most common 
adverse events were mild-to-moderate injection site reac-
tions and constitutional symptoms. PVX-410 was 
immunogenic as monotherapy and, more consistently, in 
combination with lenalidomide, as demonstrated by an 
increase in the percentage of PVX-410 tetramer and inter-
feron-γ-positive specific CD3+CD8+ T lymphocytes, as 
well as by a persistent rise of vaccine-specific effector 
memory cells. In the PVX-410-alone cohort, three of 12 
patients progressed, with a median time to progression of 
36 weeks. In the combination cohort, five of 12 patients 
showed a clinical response, with one patient progressing 
and a median time to progression not reached. PVX-410 
is also under investigation in SMM in combination with 
the selective histone-deacetylase inhibitor citarinostat ± 
lenalidomide in a phase I trial (NCT02886065).  
PD-L1 peptide vaccine, a new molecule targeting this 
immunological checkpoint, is also currently under inves-




A phase II trial with ibrutinib (NCT02943473), a Bruton 
tyrosine kinase inhibitor, was recently closed due to poor 
accrual and an unfavorable risk/benefit ratio in patients 
with high-risk SMM.   
 
 
General considerations  
Despite the many ongoing and planned studies, only 
one randomized trial has so far demonstrated a signifi-
cant survival benefit for early active therapy of high-risk 
SMM.82 Another recent trial showed an improvement in 
progression-free survival, but follow-up is still too short 
for adequate evaluation of overall survival.84 
Both these studies raised some concerns. Their sample 
size was limited, with less than 100 patients in each arm. 
The Spanish study was conducted between 2007 and 
2013,80 when some new MM drugs were not available, 
while bone involvement was assessed by a low-sensitivi-
ty technique such as plain radiography. Thus the survival 
benefit in some patients could have been due to treating 
active MM, rather than SMM. Furthermore, patients in 
the control group could start therapy only after meeting 
CRAB criteria, which may be difficult in patients with 
progressive deterioration of renal function or anemia, 
because they would start therapy before the cut-off is 
reached. On the other hand, in the US trial, the high dis-
continuation rate and the fact that the group achieving 
the most significant benefit with lenalidomide in terms of 
progression-free survival included only 25 patients could 
be concerns.84  
Notwithstanding, all ongoing studies seem to take a 
survival benefit for granted, as they do not include an 
untreated control group or compare two arms with active 
treatments, thus substantially accepting the philosophy 
that high-risk SMM “should” be treated. However, while 
some experts suggest that the Soutwest Oncology Group 
and Spanish trials should represent the current standard 
of care for patients with high-risk SMM,8,11 others are not 
convinced.10,14 Studies underway will likely show a 
response to therapy, more or less pronounced depending 
on the drugs used, with consequent improvement of pro-
gression-free survival. However, whether these often 
intensive treatments with novel agents will also have an 
extensive impact on overall survival of SMM patients will 
not be formally addressed and could remain unclear. The 
key issue remains to identify patients with high-risk 
SMM who “must” receive a treatment, because they will 
certainly have a significantly longer survival. 
 
 
Recommendations for clinical practice and 
future research 
Which diagnostic procedures are necessary for  
diagnosing smoldering multiple myeloma? 
An adequate diagnostic work-up for SMM should 
include a hemogram and biochemistry with renal function 
and calcium levels, morphological and (if available) pheno-
typic quantification of clonal plasma cells in bone marrow 
smears and bone trephine biopsy, with cytogenetics by flu-
orescence in situ hybridization or a validated equivalent 
molecular method on purified plasma cells, evaluation of 
serum and urinary M-component, total serum 
immunoglobulins, serum involved/uninvolved FLC ratio 
and their absolute values. Diagnostic imaging should com-
prise low-dose whole-body CT and whole-body MRI, if 
low-dose whole-body CT is negative. Axial MRI or PET-
CT are reasonable alternatives, according to availability 
and specific diagnostic needs, as previously detailed.   
How should current predictive models be applied in the 
setting of smoldering multiple myeloma? 
Prediction of progression to overt MM of SMM should 
be based on routine and universally applicable tests, con-
sidering, however, that proposed models may show signif-
icant discordances in identifying “true” high-risk SMM.101 
All the clinical prognostic scores reported above, particular-
ly the updated 2/20/20 model (endorsed by the IMWG and 
including variables that reflect both disease burden and 
biological features of SMM that can be measured by most 
centers), represent important tools that physicians must 
routinely use (whatever they select) for risk stratification, 
to reasonably predict the outcome of different patients 
with SMM, because their management should be risk-
adapted. Combination with appropriate imaging investiga-
tion is also recommended. 
Although more sophisticated genomic facilities may be 
available at specialized academic research institutions 
(where fluorescence in situ hybridization is replaced by 
tests such as whole exome sequencing), they are not 
mandatory, as not yet routinely used and validated for clin-
ical purposes. 
Should patients with smoldering multiple myeloma be 
informed according to their different risk of evolution?  
Due to the heterogeneous behavior of SMM, appropri-
ate information about their possible future clinical out-
come should be given to patients with either lower- or 
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higher-risk SMM, as defined by current risk models. The 
possibility of enrollment in a clinical trial, if available, 
should also be proposed.   
How should smoldering multiple myeloma  
be monitored?   
Once diagnosed, SMM patients should be monitored 
according to the above-reported recommendations, tak-
ing into particular account the individual risk of progres-
sion. Changes in serum M-component represent the most 
simple, useful and worldwide available biomarker of pro-
gression over time. Serum FLC monitoring has also been 
demonstrated to be useful in this setting.102 However, for 
all SMM patients, it is important to follow the evolution 
of multiple different parameters that, taken together, may 
give better and comprehensive insight into the dynamics 
of the disease. Imaging should be periodically repeated, 
as previously detailed, and also performed if there is a 
biochemical or clinical suspicion of disease progression.  
Which patients with smoldering multiple myeloma 
might benefit from early treatment?   
Regarding patients with lower-risk SMM, diagnosed 
according to current criteria, only active observation is 
recommended. 
With regard to early treatment of high-risk SMM, there 
is no consensus yet. Two prospective randomized trials 
have shown significant benefits from treatment with 
lenalidomide ± dexamethasone in these patients, but they 
were not registration studies and they were not presented 
to regulatory agencies.80,84 However, it should be consid-
ered that patients presenting with the coexistence of mul-
tiple risk factors, particularly increasing M-component 
levels or BMPC count or a significant decrease in hemo-
globin concentration, high FLC ratio and/or high-risk 
cytogenetics, will further increase their risk of progres-
sion. For those cases, physicians may consider starting 
early treatment, with the intention of either delaying pro-
gression or even achieving a cure. However, it will be the 
individual physician’s responsibility to seek active 
risk/benefit discussion with their patients, also consider-
ing that health-related quality of life is an essential out-
come parameter.103 The decision regarding treatment will 
also depend on whether such an unlicensed treatment 
approach falls within the legal framework of the national 
healthcare system. The Expert Panel agreed that therapy 
in these selected, very high-risk SMM patients, should be 
similar to that offered to patients with active MM, and 
that their treatment should be administered in a con-
trolled setting, such as a clinical trial.104  
What should be done in the near future to further 
improve the management of smoldering multiple 
myeloma? 
It is quite difficult to compare the results of the treat-
ments that are currently being assessed in SMM, because 
of the substantial differences in times at which the stud-
ies were conducted, definitions of high-risk SMM, inten-
sities of therapeutic approaches, and criteria/methods to 
evaluate response and progression across these studies. 
Thus, before definitively changing the current paradigms 
for the management of SMM, comparable future trials 
will have to be performed, aiming to define the follow-
ing, relevant primary objectives: (i) to identify new pre-
dictive biomarkers (clinical, molecular/genomics, 
immunological, microenvironmental, imaging) for further 
refining risk prediction and selecting SMM patients who 
may do well with observation (“Dr. Jekyll”) and those 
who require more stringent monitoring in order to estab-
lish the most appropriate moment to start treatment (“Mr. 
Hyde”). In this setting, possible racial diversities should 
also be considered, as they may have an impact on SMM 
biology;105 (ii) to assess the necessary balance between 
reduced risk of progression (and of consequent MM com-
plications) with early treatment versus possible short- and 
long-term adverse effects, specifically deteriorating 
health-related quality of life, secondary primary malig-
nancies and induction of refractory disease, elucidating, 
in particular, whether early treatment may select resistant 
clones or, the opposite, if delaying therapy may favor dis-
ease that is more resistant to future therapies; and (iii) to 
determine what intensity and which type of treatment 
are preferable in selected patients with high-risk SMM, 
i.e., short-term, intensive approaches with “curative” 
intent versus prolonged immunological control of the dis-
ease, for example by targeting immunity with memory to 
provide long-term surveillance, according to a “preven-
tive” strategy. Both these approaches should have the pri-
mary objective of improving overall survival, without 
negatively affecting health-related quality of life.  
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